Clinical Trial Update: A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial to determine the optimal dose of BNT323 in combination with BNT327 for advanced breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Unresectable Breast Cancer

Drugs mentioned

• BNT323
• BNT327

Snippet

Sponsor: BioNTech SE | Conditions: Locally Advanced Breast Cancer, Unresectable Breast Carcinoma | Phase 1, Phase 2 | Status: RECRUITING